Literature DB >> 1370411

Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules.

A Geluk1, W Bloemhoff, R R De Vries, T H Ottenhoff.   

Abstract

CD4+ T cells recognize antigenic peptides bound to the polymorphic peptide-binding site of major histocompatibility complex (MHC) class II molecules. The polymorphism of this site is thought to dictate which peptides can be bound and thus presented to the T cell receptor. The mycobacterial 65-kDa heat-shock protein (hsp65) peptide 3-13 is an important T cell epitope: it is immunodominant in the mycobacterium-specific T cell response of HLA-DR3+ individuals but, interestingly cannot be recognized in the context of any other HLA-DR molecules. We, therefore, have tested whether the hsp65 epitope p3-13 is selected for T cell recognition in the context of only HLA-DR3 molecules by an unique binding specificity for HLA-DR3. Using biotinylated peptides and EBV-transformed BLCL comprising all known HLA class II specificities, we find that p3-13 binds to HLA-DRw17(DR3) but not to any other HLA-DR molecule. Conversely, a control peptide p307-319 influenza hemagglutinin binds to all known HLA-DR molecules but only weakly to HLA-DRw17 and HLA-DR9. Peptide binding could be inhibited by excess unbiotinylated competitor analogue as well as by anti-DR monoclonal antibodies but not by anti-class I-, anti-DP- or anti-DQ monoclonal antibodies. The amino acid sequence of DRw17 molecules differs uniquely at five positions from the other DR beta 1 sequences. Three of these five residues (positions 26, 71 and 74) are potential peptide contacting residues. These residues map closely together in the hypothetical three-dimensional model of the DR molecule and, thus, most probably form a positively charged pocket, critical for the binding of p3-13. Interestingly, p3-13 does not bind to a DR3 variant, the DRw18 molecule. The DRw18 beta 1 chain differs from DRw17 at two major positions, close to or within the DRw17-specific pocket. These substitutions drastically change the structure and charge of the pocket and thus presumably abrogate its ability to bind p3-13.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370411     DOI: 10.1002/eji.1830220117

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Flexibility in T-cell receptor ligand repertoires depends on MHC and T-cell receptor clonotype.

Authors:  A Geluk; K E van Meijgaarden; T H Ottenhoff
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

2.  Definition of a human suppressor T-cell epitope.

Authors:  T Mutis; Y E Cornelisse; G Datema; P J van den Elsen; T H Ottenhoff; R R de Vries
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

3.  Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide.

Authors:  X T Fu; C P Bono; S L Woulfe; C Swearingen; N L Summers; F Sinigaglia; A Sette; B D Schwartz; R W Karr
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

4.  An epitope delivery system for use with recombinant mycobacteria.

Authors:  C Hetzel; R Janssen; S J Ely; N M Kristensen; K Bunting; J B Cooper; J R Lamb; D B Young; J E Thole
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

Review 5.  Vaccines against tuberculosis: where are we and where do we need to go?

Authors:  Tom H M Ottenhoff; Stefan H E Kaufmann
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823

6.  A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.

Authors:  E Mellins; P Cameron; M Amaya; S Goodman; D Pious; L Smith; B Arp
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

7.  Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates.

Authors:  A Geluk; D G Elferink; B L Slierendregt; K E van Meijgaarden; R R de Vries; T H Ottenhoff; R E Bontrop
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.